Journal of Clinical and Translational Endocrinology最新文献

{"title":"Bone health and fracture prevention after kidney transplantation","authors":"Vishal Jaikaransingh","doi":"10.1016/j.jcte.2024.100345","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100345","url":null,"abstract":"<div><p>Changes in bone health and strength are common after kidney transplantation and can lead to an increased risk of fracture. This has implications for morbidity, mortality and renal allograft survival. This review will focus on the changes that occur in bone health and fracture risk after kidney transplantation and examine the evidence available to guide diagnostic and therapeutic decisions with the aim of fracture prevention.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100345"},"PeriodicalIF":3.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000164/pdfft?md5=606c703ed432c8d66e6cd07a3e63220a&pid=1-s2.0-S2214623724000164-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140822877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and acceptability of a culturally competent skills and knowledge assessment tool for patients with diabetes mellitus","authors":"Stephanie Hakimian ,&nbsp;Susan Karam ,&nbsp;Kim Pardilla ,&nbsp;Kasey Coyne ,&nbsp;Emilie K. Touma ,&nbsp;Diane Larsen ,&nbsp;Jane L. Holl ,&nbsp;Amisha Wallia","doi":"10.1016/j.jcte.2024.100346","DOIUrl":"10.1016/j.jcte.2024.100346","url":null,"abstract":"<div><h3>Background</h3><p>Patients newly diagnosed with type 2 diabetes mellitus (DM) and newly prescribed insulin need to learn essential self-care and management skills quickly. To optimize teaching, clinicians need to assess a patient’s basic understanding of DM and their skills. While DM patient assessments exist, this study reports the development of an assessment of patient DM management skills and knowledge, using feedback from DM clinicians, patients, and caregivers.</p></div><div><h3>Research Design and Methods</h3><p>A systematic search of Pubmed/Medline and Scopus (1980–2017) of DM knowledge assessments was performed. Twenty-four studies were identified. Content from the existing assessments was adapted to create a 12 item DM-Skills Knowledge Assessment (SKA) to assess a patient’s DM management skills and knowledge. To assess cultural humility, modified cognitive interviews were conducted in individual user sessions and semi-structured focus groups. Audio-transcripts of the interviews/focus groups were independently coded, and codes were grouped into key themes. Participant demographic characteristics were assessed.</p></div><div><h3>Results</h3><p>Five focus groups and eleven key informant interviews were conducted, including 10 DM clinicians, 12 patients/caregivers, and 15 laypersons. All 10 clinicians reported that the DM-SKA addresses the key domains of DM education deemed to be of highest importance during the transition from hospital to home and that their patients would be willing to complete the assessment. More than half of the patient/caregiver/layperson participants self-reported race/ethnicity other than non-Hispanic white and performed similarly to non-Hispanic white participants in understanding each item, willingness to complete the DM-SKA, and perception that family or community members would be willing to complete the DM-SKA. The DM-SKA has a baseline Flesch reading score of 81.3, indicating low complexity language.</p></div><div><h3>Conclusion</h3><p>DM clinicians agreed that the DM-SKA assesses all essential DM management skills. For patients/caregivers, it has acceptable literacy, cognitive validity, and culturally acceptable for racial/ethnic minority populations in the study, including elderly persons.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100346"},"PeriodicalIF":3.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000176/pdfft?md5=d39e54ecec04fe73442e0286ba3b827b&pid=1-s2.0-S2214623724000176-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140764251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment","authors":"Malinda Wu ,&nbsp;Jacob D. Davis ,&nbsp;Conan Zhao ,&nbsp;Tanicia Daley ,&nbsp;Kathryn E. Oliver","doi":"10.1016/j.jcte.2024.100344","DOIUrl":"10.1016/j.jcte.2024.100344","url":null,"abstract":"<div><p>Cystic fibrosis (CF) has been traditionally viewed as a disease that affects White individuals. However, CF occurs among all races, ethnicities, and geographic ancestries. The disorder results from mutations in the <em>CF transmembrane conductance regulator</em> (<em>CFTR</em>). Varying incidence of CF is reported among Black, Indigenous, and People of Color (BIPOC), who typically exhibit worse clinical outcomes. These populations are more likely to carry rare <em>CFTR</em> variants omitted from newborn screening panels, leading to disparities in care such as delayed diagnosis and treatment. In this study, we present a case-in-point describing an individual of Gambian descent identified with CF. Patient genotype includes a premature termination codon (PTC) (c.2353C&gt;T) and previously undescribed single nucleotide deletion (c.1970delG), arguing against effectiveness of currently available CFTR modulator-based interventions. Strategies for overcoming these two variants will likely include combinations of PTC suppressors, nonsense mediated decay inhibitors, and/or alternative approaches (e.g. gene therapy). Investigations such as the present study establish a foundation from which therapeutic treatments may be developed. Importantly, c.2353C&gt;T and c.1970delG were not detected in the patient by traditional <em>CFTR</em> screening panels, which include an implicit racial and ethnic diagnostic bias as these tests are comprised of mutations largely observed in people of European ancestry. We suggest that next-generation sequencing of <em>CFTR</em> should be utilized to confirm or exclude a CF diagnosis, in order to equitably serve BIPOC individuals. Additional epidemiologic data, basic science investigations, and translational work are imperative for improving understanding of disease prevalence and progression, <em>CFTR</em> variant frequency, genotype-phenotype correlation, pharmacologic responsiveness, and personalized medicine approaches for patients with African ancestry and other historically understudied geographic lineages.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100344"},"PeriodicalIF":3.0,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000152/pdfft?md5=5090e775b1523be2a90facba1ac9ddce&pid=1-s2.0-S2214623724000152-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140775798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes","authors":"Moeber Mohammed Mahzari ,&nbsp;Omar Buraykan Alluhayyan ,&nbsp;Mahdi Hamad Almutairi ,&nbsp;Mohammed Abdullah Bayounis ,&nbsp;Yazeed Hasan Alrayani ,&nbsp;Amir A. Omair ,&nbsp;Awad Saad Alshahrani","doi":"10.1016/j.jcte.2024.100343","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100343","url":null,"abstract":"<div><h3>Objective</h3><p>Type 2 diabetes mellitus (T2DM) and post-transplant diabetes mellitus (PTDM) are common in renal transplant recipients. Semaglutide has demonstrated efficacy and safety in patients with T2DM. To date, only a limited number of studies have investigated its use in renal transplant patients. This study assessed the safety and efficacy of semaglutide in post-renal transplant patients.</p></div><div><h3>Methods</h3><p>A retrospective study was conducted at king Abdulaziz Medical City-Riyadh, Saudi Arabia. The subjects of the study were adults and adolescents (&gt;14 years) who had undergone a kidney transplant and had pre-existing T2DM or PTDM. The study subjects were given semaglutide during the study period, from January 2018 to July 2022. The data were collected over a period of 18 months.</p></div><div><h3>Results</h3><p>A total of 39 patients were included, 29 (74 %) of whom were male. A significant decrease in hemoglobin A1c (HbA1c) was observed during the follow-up period when compared to baseline (8.4 %±1.3 % at baseline vs. 7.4 %±1.0 % at 13–18 months (p &lt; 0.001). A significant reduction in weight was also noted at follow-up as compared to baseline (99.5 kg ± 17.7 vs 90.7 kg ± 16.8 at 13–18 months (p &lt; 0.001). No significant changes were found in renal graft function markers.</p></div><div><h3>Conclusion</h3><p>Semaglutide was found to significantly reduce HbA1c levels and weight in post renal transplant patients with diabetes. No significant changes in markers of renal graft function were observed.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100343"},"PeriodicalIF":3.0,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000140/pdfft?md5=347e3e769ad4860c814d5d6d05fc57b6&pid=1-s2.0-S2214623724000140-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140536961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)","authors":"Mariam M. Ali ,&nbsp;Sanober Parveen ,&nbsp;Vanessa Williams ,&nbsp;Robert Dons ,&nbsp;Gabriel I. Uwaifo","doi":"10.1016/j.jcte.2024.100341","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100341","url":null,"abstract":"<div><p>Obesity and chronic kidney disease are two ongoing progressive clinical pandemics of major public health and clinical care significance. Because of their growing prevalence, chronic indolent course and consequent complications both these conditions place significant burden on the health care delivery system especially in developed countries like the United States. Beyond the chance coexistence of both of these conditions in the same patient based on high prevalence it is now apparent that obesity is associated with and likely has a direct causal role in the onset, progression and severity of chronic kidney disease. The causes and underlying pathophysiology of this are myriad, complicated and multi-faceted. In this review, continuing the theme of this special edition of the journal on “ The Cross roads between Endocrinology and Nephrology” we review the epidemiology of obesity related chronic kidney disease (ORCKD), and its various underlying causes and pathophysiology. In addition, we delve into the consequent comorbidities and complications associated with ORCKD with particular emphasis on the cardio metabolic consequences and then review the current body of evidence for available strategies for chronic kidney disease modulation in ORCKD as well as the potential unique role of weight reduction and management strategies in its improvement and risk reduction.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100341"},"PeriodicalIF":3.0,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000127/pdfft?md5=345c302048320bbf6f70bf009bc0e8a0&pid=1-s2.0-S2214623724000127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140351035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olfactory function in diabetes mellitus","authors":"Beata Sienkiewicz-Oleszkiewicz ,&nbsp;Thomas Hummel","doi":"10.1016/j.jcte.2024.100342","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100342","url":null,"abstract":"<div><p>Diabetes mellitus (DM) is an increasingly common disease in both children and adults. In addition to neuronal and/or vascular disorders, it can cause chemosensory abnormalities including olfactory deterioration. The purpose of this article is to summarize current knowledge on olfactory function in DM, highlighting the impact of co-morbidities, especially obesity, thyroid dysfunction, chronic kidney disease and COVID-19 on olfactory outcomes. Research to date mostly shows that olfactory impairment is more common in people with diabetes than in the general population. In addition, the presence of concomitant diseases is a factor increasing olfactory impairment. Such a correlation was shown for type 1 diabetes, type 2 diabetes and gestational diabetes. At the same time, not only chronic diseases, but also DM in acute conditions such as COVID-19 leads to a higher prevalence of olfactory disorders during infection. Analyzing the existing literature, it is important to be aware of the limitations of published studies. These include the small number of patients studied, the lack of uniformity in the methods used to assess the sense of smell, frequently relying on rated olfactory function only, and the simultaneous analysis of patients with different types of diabetes, often without a clear indication of diabetes type. In addition, the number of available publications is small. Certainly, further research in this area is needed. From a practical point of view decreased olfactory performance may be an indicator for central neuropathy and an indication for assessing the patient's nutritional status, examining cognitive function, especially in older patients and performing additional diagnostic tests, such as checking thyroid function, because all those changes were correlated with smell deterioration.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100342"},"PeriodicalIF":3.0,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000139/pdfft?md5=dd014507ee998a4d38dcf5c11f389f78&pid=1-s2.0-S2214623724000139-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140345352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-inflammatory benefits of semaglutide: State of the art","authors":"Habib Yaribeygi ,&nbsp;Mina Maleki ,&nbsp;Tannaz Jamialahmadi ,&nbsp;Amirhossein Sahebkar","doi":"10.1016/j.jcte.2024.100340","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100340","url":null,"abstract":"<div><p>Individuals with diabetes often have chronic inflammation and high levels of inflammatory cytokines, leading to insulin resistance and complications. Anti-inflammatory agents are proposed to prevent these issues, including using antidiabetic medications with anti-inflammatory properties like semaglutide, a GLP-1 analogue. Semaglutide not only lowers glucose but also shows potential anti-inflammatory effects. Studies suggest it can modulate inflammatory responses and benefit those with diabetes. However, the exact mechanisms of its anti-inflammatory effects are not fully understood. This review aims to discuss the latest findings on semaglutide's anti-inflammatory effects and the potential pathways involved.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100340"},"PeriodicalIF":3.0,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000115/pdfft?md5=314c8acf016d37fe0cc568a3018202bd&pid=1-s2.0-S2214623724000115-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140321117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telemedicine care coordination and visit frequency in pediatric patients with type 1 diabetes in Oregon","authors":"Emily S. Mitchell ,&nbsp;Sarah Andrea ,&nbsp;Ines Guttmann-Bauman","doi":"10.1016/j.jcte.2024.100338","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100338","url":null,"abstract":"<div><h3>Introduction</h3><p>Children with type 1 diabetes require close monitoring with visits every 3–4 months. COVID-19-induced telemedicine expansion may alleviate the challenge of high visit frequency that children with type 1 diabetes face. However, telemedicine’s impact on access to care may be limited if patients lack adequate support for telemedicine. The purpose of this study was to evaluate the impact of telemedicine care coordination services on visit frequency in an urban medical center without care coordination services versus a rural outreach program with established care coordination services serviced by the same providers.</p></div><div><h3>Methods</h3><p>We evaluated EHR data from 790 children receiving care between July 2018 and December 2021 at a single academic center in Oregon. We estimated differences in likelihood of adequately timed monitoring care over time by patient care coordination services status using Generalized Estimating Equations.</p></div><div><h3>Results</h3><p>Just prior to telemedicine expansion, patients receiving care coordination services were 25.6 % less likely to receive adequately timed monitoring care (95 % CI: 51.6 %, 114 %). Following telemedicine expansion, likelihood of adequately timed monitoring care increased from 28.8 % to 58.2 % among those receiving care coordination services and decreased from 38.7 % to 22.0 % among those not receiving care coordination services; increases in adequately timed monitoring care were 3.55 times greater in patients receiving care coordination services relative to those not (95 % CI: 2.10, 6.01).</p></div><div><h3>Discussion</h3><p>For pediatric patients with type 1 diabetes, telemedicine care coordination may be an important factor for increasing visit adherence and may increase the number of patients meeting goal visit frequency beyond levels seen prior to widespread telemedicine availability.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100338"},"PeriodicalIF":3.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000097/pdfft?md5=fd6657c5e0847b78cefe19ec67e4f8dd&pid=1-s2.0-S2214623724000097-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 impacts and inequities among underserved communities with diabetes","authors":"Jennifer L. Maizel ,&nbsp;Michael J. Haller ,&nbsp;David M. Maahs ,&nbsp;Ananta Addala ,&nbsp;Rayhan A. Lal ,&nbsp;Stephanie L. Filipp ,&nbsp;Matthew J. Gurka ,&nbsp;Sarah Westen ,&nbsp;Brittney N. Dixon ,&nbsp;Lauren Figg ,&nbsp;Melanie Hechavarria ,&nbsp;Keilecia G. Malden ,&nbsp;Ashby F. Walker","doi":"10.1016/j.jcte.2024.100337","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100337","url":null,"abstract":"<div><h3>Background</h3><p>People with diabetes have higher COVID-19 morbidity and mortality. These risks are amplified for underserved communities including racial/ethnic minorities and people with lower socioeconomic status. However, limited research has examined COVID-19 outcomes specifically affecting underserved communities with diabetes.</p></div><div><h3>Methods</h3><p>From November 2021 to July 2022, adults with insulin-requiring diabetes at federally qualified health centers in Florida and California (n = 450) completed surveys examining COVID-19 outcomes and demographics. Surveys assessed COVID-19 severity, vaccination uptake, mask-wearing habits, income changes, and healthcare access changes. Surveys also included the full Coronavirus Anxiety Scale (CAS-19). Descriptive statistics were computed for all outcomes. Between-group comparisons for state and race/ethnicity were evaluated via Chi-Squared, Fisher’s Exact, Cochran-Mantel-Haenszel, One-Way ANOVA, and <em>t</em>-tests. Logistic regression determined factors associated with COVID-19 vaccination uptake. Data were self-reported and analyzed cross-sectionally.</p></div><div><h3>Results</h3><p>Overall, 29.7 % reported contracting COVID-19; of those, 45.3 % sought care or were hospitalized. Most (81.3 %) received ≥ 1 vaccine. Hispanics had the highest vaccination rate (91.1 %); Non-Hispanic Blacks (NHBs) had the lowest (73.9 %; p =.0281). Hispanics had 4.63x greater vaccination odds than Non-Hispanic Whites ([NHWs]; 95 % CI = [1.81, 11.89]). NHWs least often wore masks (18.8 %; p &lt;.001). Participants reported pandemic-related healthcare changes (62 %) and higher costs of diabetes medications (41 %). Income loss was more frequent in Florida (76 %; p &lt;.001). NHBs most frequently reported “severe” income loss (26.4 %; p =.0124). Loss of health insurance was more common among NHBs (13.3 %; p =.0416) and in Florida (9.7 %; p =.039). COVID-19 anxiety was highest among NHBs and Hispanics (IQR = [0.0, 3.0]; p =.0232) and in Florida (IQR = [0.0, 2.0]; p =.0435).</p></div><div><h3>Conclusions</h3><p>Underserved communities with diabetes had high COVID-19 vaccine uptake but experienced significant COVID-19-related physical, psychosocial, and financial impacts. NHBs and those in Florida had worse outcomes than other racial/ethnic groups and those in California. Further research, interventions, and policy changes are needed to promote health equity for this population.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100337"},"PeriodicalIF":3.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000085/pdfft?md5=7d5c3260b4a794478b1c86202bdb0908&pid=1-s2.0-S2214623724000085-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140191970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 inhibitors: Beyond glycemic control","authors":"Irtiza Hasan ,&nbsp;Tasnuva Rashid ,&nbsp;Vishal Jaikaransingh ,&nbsp;Charles Heilig ,&nbsp;Emaad M. Abdel-Rahman ,&nbsp;Alaa S. Awad","doi":"10.1016/j.jcte.2024.100335","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100335","url":null,"abstract":"<div><p>Multiple randomized controlled trials have extensively examined the therapeutic effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors, ushering in a transformative approach to treating individuals with type 2 diabetes mellitus (DM). Notably, emerging reports have drawn attention to the potential positive impacts of SGLT2 inhibitors in nondiabetic patients. In an effort to delve into this phenomenon, a comprehensive systematic literature review spanning PubMed (NLM), Medline (Ovid), and Cochrane Library, covering publications from 2000 to 2024 was undertaken. This systematic review encompassed twenty-six randomized control trials (RCTs) involving 35,317 participants. The findings unveiled a multifaceted role for SGLT2 inhibitors, showcasing their ability to enhance metabolic control and yield cardioprotective effects through a reduction in cardiovascular death (CVD) and hospitalization related to heart failure (HF). Additionally, a renalprotective effect was observed, evidenced by a slowdown in chronic kidney disease (CKD) progression and a decrease in albuminuria. Importantly, these benefits were coupled with an acceptable safety profile. The literature also points to various biological plausibility and underlying mechanistic pathways, offering insights into the association between SGLT2 inhibitors and these positive outcomes in nondiabetic individuals. Current research trends indicate a continual exploration of additional role for SGLT2 inhibitors in. Nevertheless, further research is imperative to fully elucidate the mechanisms and long-term outcomes associated with the nondiabetic use of SGLT2 inhibitors.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"35 ","pages":"Article 100335"},"PeriodicalIF":3.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000061/pdfft?md5=d2676b62a0044b202fed595b731c714f&pid=1-s2.0-S2214623724000061-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140139052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}